November 1, 2023 07:30 AM EDT
Financing
Startups
Cell/Gene Tx

Cana­di­an gene ther­a­py biotech en­Gene starts trad­ing on Nas­daq af­ter com­plet­ing For­bion SPAC deal

Kyle LaHucik

Senior Reporter

Gene ther­a­py start­up en­Gene be­came a pub­lic biotech on Wednes­day af­ter com­plet­ing its com­bi­na­tion with For­bion Eu­ro­pean Ac­qui­si­tion, a blank check com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times